Stocktoria
Innoviva, Inc. INVA
Innoviva, Inc. (INVA) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.00% (safety: no dividend).
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.415 |
| Retained earnings / assets | 0.165 |
| EBIT / assets | 0.1 |
| Equity / liabilities | 2.537 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| INVA | Innoviva, Inc. | 3/9 | 6.59 | — | +14.7% |
| ARDX | ARDELYX, INC. | 2/9 | -2.34 | — | +22.1% |
| ESPR | Esperion Therapeutics, Inc. | 3/9 | -8.63 | — | +21.3% |
| SVA | SINOVAC BIOTECH LTD | 3/9 | 8.06 | — | +6.8% |
| ARQT | Arcutis Biotherapeutics, Inc. | 4/9 | -3.68 | — | +91.3% |
| ZLAB | Zai Lab Ltd | 3/9 | -3.61 | — | +15.3% |
| MNKD | MANNKIND CORP | 3/9 | -11.89 | 218.2 | +22.2% |
About Innoviva, Inc.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
FAQ
Is INVA financially healthy?
Innoviva, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does INVA pay a dividend, and is it safe?
Yes. Innoviva, Inc. pays a dividend yielding about 0.00% with a None payout ratio, rated “no dividend” for safety.
Is INVA overvalued or undervalued?
Innoviva, Inc. trades at about 6.3× trailing earnings — below its 10-year norm (10-year range 4.8×–51.8×, median 7.4×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for INVA?
The average Wall-Street price target for Innoviva, Inc. is $35.50, about 70.6% above the recent price, from 4 analysts (consensus: buy).
Is INVA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Innoviva, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone, a dividend yield of 0.00%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.